The Drumbeat of Disinflation: Why the Federal Reserve is Poised to Cut Rates Once More
Healthcare Shorts Take a Breather, But Moderna Remains Under the Microscope
Navigating the Path to Approval: Why REGENXBIO (RGNX) Remains a Strong Investment with RGX-121 for Hunter Syndrome